AMARIN CORP PLC\UK Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two
AMARIN CORP PLC\UK (AMRN) had Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two of $127.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Leases › Sales-Type and Direct Financing Leases, Payment to be Received, Fiscal Year Maturity
us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears · last filed 2026-07-29
- 2026-06-30: Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two $127.00K.
- 2026-03-31: Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two $127.00K.
- 2025-12-31: Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two $125.00K.
- 2025-09-30: Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two $125.00K.
| Period end | Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two | Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two as first filed |
|---|---|---|
| 2026-06-30 | $127.00K 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $127.00K 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $125.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $125.00K 10-Q · filed 2025-10-29 | |
| 2025-03-31 | $125.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $122.00K 10-K · filed 2025-03-12 | |
| 2024-09-30 | $125.00K 10-Q · filed 2025-07-30 | $122.00K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $122.00K 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $122.00K 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $119.00K 10-K · filed 2024-02-29 | |
| 2023-09-30 | $119.00K 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $119.00K 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $119.00K 10-Q · filed 2023-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |